NCT06878976 - Open-Label Safety Study of Solriamfetol in Subjects with Binge Eating Disorder | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Binge-Eating Disorder

Interventions

DRUG

Solriamfetol 75mg, 150 mg, or 300 mg

Taken once daily.

Trial Locations (18)

10128

Clinical Research Site, New York

10549

Clinical Research Site, Mount Kisco

27607

Clinical Research Site, Raleigh

30060

Clinical Research Site, Marietta

32256

Clinical Research Site, Jacksonville

33012

Clinical Research Site, Hialeah

33176

Clinical Research Site, Miami

33912

Clinical Research Site, Fort Myers

38119

Clinical Research Site, Memphis

44720

Clinical Research Site, North Canton

45215

Clinical Research Site, Cincinnati

63304

Clinical Research Site, Saint Charles

66210

Clinical Research Site, Overland Park

75251

Clinical Research Site, Dallas

78731

Clinical Research Site, Austin

91316

Clinical Research Site, Encino

94596

Clinical Research Site, Walnut Creek

06416

Clinical Research Site, Cromwell